If the IMPROVE-IT Trial Was Positive, as Reported, Why Did the FDA Denied Expanded Approval for Ezetimibe and Simvastatin? An Explanation of the Tipping Point Analysis

Emma P. Deloughery, Vinay Prasad

Research output: Contribution to journal › Editorial › peer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'If the IMPROVE-IT Trial Was Positive, as Reported, Why Did the FDA Denied Expanded Approval for Ezetimibe and Simvastatin? An Explanation of the Tipping Point Analysis'. Together they form a unique fingerprint.